Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Report from the ESMO 2018 Congress, Munich, October 19th–23rd, 2018

Report from the ESMO 2018 Congress, Munich, October 19th–23rd, 2018 special issue ESMO 2018 ESMO 2018 Table of Contents S70 Preface S70 Checkpoint inhibition excels in all treatment lines S73 EGFR-mutant lung cancer: what’s new with respect to activity and resistance? S77 Interview: Several reasons support sequenc- ing of EGFR TKI treatment S78 Potent treatment options in ALK- and MET- positive disease Editorial Board: Alex A. Adjei, MD, PhD, Mayo Clinic, Department of Oncology, Rochester, Minnesota, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Frau Vera Hirsh, MD, McGill University, Health Centre, Montreal, Quebec, Canada Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Herbert H F Loong, MD, The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan, Italy Barbara Melosky, MD, FRCPC, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada Nir http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Report from the ESMO 2018 Congress, Munich, October 19th–23rd, 2018

memo - Magazine of European Medical Oncology , Volume 11 (4) – Nov 29, 2018
Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/report-from-the-esmo-2018-congress-munich-october-19th-23rd-2018-yfPN02v08H

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-018-0464-3
Publisher site
See Article on Publisher Site

Abstract

special issue ESMO 2018 ESMO 2018 Table of Contents S70 Preface S70 Checkpoint inhibition excels in all treatment lines S73 EGFR-mutant lung cancer: what’s new with respect to activity and resistance? S77 Interview: Several reasons support sequenc- ing of EGFR TKI treatment S78 Potent treatment options in ALK- and MET- positive disease Editorial Board: Alex A. Adjei, MD, PhD, Mayo Clinic, Department of Oncology, Rochester, Minnesota, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Frau Vera Hirsh, MD, McGill University, Health Centre, Montreal, Quebec, Canada Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Herbert H F Loong, MD, The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan, Italy Barbara Melosky, MD, FRCPC, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada Nir

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 29, 2018

There are no references for this article.